Castle Biosciences CEO Derek J. Maetzold disposes of 550 common shares worth $12,606 - CSTL News | RalliesCastle Biosciences CEO Derek J. Maetzold disposes of 550 common shares worth $12,606
C
CSTL• CEO share sale and option exercise
- Castle Biosciences CEO Derek J. Maetzold exercised stock options for 550 shares at USD 2.39 on July 14, 2026.
- Maetzold sold 550 shares at a weighted-average USD 22.92, cutting his direct stake to 21,479 shares.
- Trust-held positions also fell via sales at USD 22.92, including 1,357 shares from The Maetzold Descendants 2020 Trust.
BFAM
•
